Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells

GLIA

Volumn 29, Issue 1, 2000, Pages 58-69

  Puffenbarger, Robyn A ^a   Boothe, A Catherine ^a   Cabral, Guy A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

9 tetrahydrocannabinol; Anandamide; Cannabinoid receptor; IL 1 ; IL 1 ; IL 6; TNF

Indexed keywords

ANALGESIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR CB2, RAT; CD14 ANTIGEN; CYTOKINE; DRUG RECEPTOR; GAMMA INTERFERON; INTERLEUKIN DERIVATIVE; LIPOPOLYSACCHARIDE; LYMPHOTOXIN; MESSENGER RNA; PSYCHOTROPIC AGENT; RIBONUCLEASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MICROGLIA; RAT; SPRAGUE DAWLEY RAT; STEREOISOMERISM;

ANALGESICS; ANIMALS; ANTIGENS, CD14; CALCIUM CHANNEL BLOCKERS; CANNABINOIDS; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERFERON TYPE II; INTERLEUKINS; LIPOPOLYSACCHARIDES; LYMPHOTOXIN-ALPHA; MICROGLIA; PSYCHOTROPIC DRUGS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; RIBONUCLEASES; RNA, MESSENGER; STEREOISOMERISM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033986604     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.0.CO;2-W     Document Type: Article

References (34)

1. Aloisi F, Ria F, Penna G, Adorini L. 1998. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol 160:4671-4680.
2. Cabrai GA, Toney DM, Fischer SK, Harrison MP, Marciano CF. 1995. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci 56:2065-2072.
3. Compton DR, Rice KC, De CB, Razdan RK, Melvin LS, Johnson MR, Martin BR. 1993. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218-226.
4. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. 1997. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276:589-592.
5. Deutsch DG, Chin SA. 1993. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796.
6. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
7. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. 1993. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7:75-83.
8. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL. 1995. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
9. Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA. 1992. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42:838-845.
10. 9-tetrahydrocannabinol inhibition of tumor necrosis factor-u: suppression of post-translation events. J Pharmacol Exp Ther 267:1558-1565.
11. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
12. Giulian D, Baker TJ. 1986. Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci 6:2163-2178.
13. Howlett AC, Qualy JM, Khachatrian LL. 1986. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29:307-313.
14. 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kappa B/Rel activation. Mol Pharmacol 50:334-341.
15. Kaminski NE, Koh WS, Yang KH, Lee M, Kessler FK. 1994. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol 48:1899-1908.
16. Klein TW, Newton C, Friedman H. 1998. Cannabinoid receptors and immunity. Immunol Today 19:373-381.
17. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW. 1993. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 150:2659-2667.
18. 1-tetrahydrocannabinol into erythrocyte membranes in vivo and its effects on membrane fluidity. Experientia 40:866-868.
19. Liu S, Khemlani LS, Shapiro RA, Johnson ML, Liu K, Geller DA, Watkins SC, Goyert SM, Billiar TR. 1998. Expression of CD14 by hepatocytes: upregulation by cytokines during endotoxemia. Infect Immun 66:5089-5098.
20. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
21. McGeer PL, McGeer EG. 1995. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21:195-218.
22. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE. 1993. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 151:2132-2141.
23. Moore S, Thanos S. 1996. The concept of microglia in relation to central nervous system disease and regeneration. Prog Neurobiol 48:441-449.
24. Munro S, Thomas KL, Abu SM. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
25. Onaivi ES, Chakrabarti A, Chaudhuri G. 1996. Cannabinoid receptor genes. Prog Neurobiol 48:275-305.
26. 1 cannabinoid receptor activity. Mol Pharmacol 54:1064-1072.
27. Portier M, Rinaldi-Carmona M, Pecceu F, Combes T, Poinot-Chazel C, Calandra B, Barth F, Le Fur G, Casellas P. 1999. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther 288:582-589.
28. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Brelière JC, Le Fur G. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
29. 2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
30. 1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. J Neuroimmunol 82:13-21.
31. Streit WJ. 1990. An improved staining method for rat microglial cells using the lectin from Griffonia simplicifolia (GSA I-B4). J Histochem Cytochem 38:1683-1686.
32. Tang JL, Lancz G, Specter S, Bullock H. 1992. Marijuana and immunity: tetrahydrocannabinol-mediated inhibition of growth and phagocytic activity of the murine cell line, P388D1. Int J Immunopharmacol 14:253-262.
33. Watanabe K, Ogi H, Nakamura S, Kayano Y, Matsunaga T, Yoshimura H, Yamamoto I. 1998. Distribution and characterization of anandamide amidohydrolase in mouse brain and liver. Life Sci 62:1223-1229.
34. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433.